Solve FSHD Holdings Ltd. as lead investor with Cambrian Biopharama Inc. in Vita Therapeutics, Inc.'s US$31 million Series B equity financing.
Cantor Fitzgerald Canada Corporation, in an up to US$35-million at-the-market equity program for the sale of common shares pursuant to an equity distribution agreement with Cybin Inc. (NEO: CYBN) (NYSE American: CYBN).
MustGrow Biologics Corp., in connection with the filing of a base shelf prospectus relating to the offering for sale, from time to time, of common shares, warrants, units, debt securities, subscription receipts or any combination thereof for aggregate gross proceeds of up to $40 million.
Stifel Nicolaus Canada Inc., in the $2.8-million overnight marketed offering of Mydecine Innovations Group Inc.
MustGrow Biologics Corp., in its non-brokered private placement for gross proceeds of $7.1-million.
A syndicate of underwriters, co-led by Leede Jones Gable Inc., in the $8.1-million bought-deal public offering of units of Ventripoint Diagnostics Ltd.
Skandinaviska Enskilda Banken AB (publ), as joint lead arranger and joint bookrunner in term loan facilities totalling $385 million and $125 million revolving credit facility made to a corporation in the medical technology industry.
United Active Living Inc., in matters related to ownership and operations of assisting living housing projects.
Kensington Capital Partners and Kensington Private Equity Fund in the $35-million acquisition and related financing through its portfolio company, Clearpoint Health Network Inc., of the surgical and medical centres business of Centric Health Corporation, a TSX listed company, and subsequent reorganization of Clearpoint . [Kensington Capital Advisors Inc. is a leading independent investor in alternative assets with over $1.5 billion invested in private equity and alternative assets.]
Emerald Health acquires Québec-based Licensed Producer Agro-Biotech.
48North Cannabis Corp., in its go-public transaction with Kramer Capital Corp.
FV Pharma Inc., in its amalgamation with Century Financial Capital Group.
Canadian counsel to Baker Technologies, Inc., a Colorado-based provider of cannabis-specific customer relationship management software, in its business combination with Santé Veritas Holdings Inc., Briteside Holdings, LLC and Sea Hunter Therapeutics, LLC.
Fluorinov Pharma Inc., a privately-held oncology company, in its $10-million acquisition by Trillium Therapeutics Inc.
Indiva Limited, in its completed $60-million reverse takeover transaction, resulting in the company's listing on the TSX Venture Exchange which was supported by a $23-million financing.
Lead counsel to Harvest One Cannabis, a global cannabis company servicing both the medical and recreational cannabis markets, in Canada and internationally, in their $60 million Canadian listing which was supported by a $25 million financing, and in $65 million of subsequent bought deal financings.
Wheaton Income (formerly Cannabis Wheaton Income Corp.), in its purchase of all of the issued and outstanding shares of RockGarden Medicinals (2014) Inc.
Teva Pharmaceutical Ltd., as Canadian counsel, in its acquisition of ratiopharm Group for approximately $4.85 billion (€3.625 billion).
NUCRYST Pharmaceuticals Corp., in the possible sale of all or substantially all of the assets of NUCRYST and the consideration of an amalgamation of the NUCRYST with 1499642 Alberta Ltd., a wholly-owned subsidiary of The Westaim Corporation.
Oncolytics Biotech Inc., in $13.8-million cross-border public offering of common shares.
Inyx Inc., in the acquisition of certain assets and business of Aventis Pharmaceuticals Puerto Rico Inc.
Protana Inc. (biotechnology), counsel to debtor, in its $40-million debt in the Companies' Creditors Arrangement Act proceedings.
Takeda Chemical Industries Limited, in a class action proceeding and individual claim litigation relating to an alleged agreement to fix prices of vitamins throughout Canada.
Matco Investments Limited, in the reorganization of Synsorb Biotech Inc. into an energy company - Hawker Energy Inc., acquisition of assets into Southward Energy Limited and related financings, valued at $170 million.
MDS Proteomics Inc., (biotechnology), counsel to debtor, in its $100-million debt, in the Companies' Creditors Arrangement Act proceedings.
NUCRYST Pharmaceuticals Corporation and The Westaim Corporation, in NUCRYST's US$45 million cross-border initial public offering, which was concurrently offered in Canada and the United States.
Valens Pharma Ltd., (formerly known as CardioMetabolics Inc.), in a brokered private placement offering of common shares for proceeds of $2.78 million led by Canaccord Capital Corporation.
Valens Pharma Ltd., (formerly known as CardioMetabolics Inc.), in a brokered private placement offering of common shares for proceeds of $4.1 million led by Canaccord Capital Corporation.